Erratum to: Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

Peter K. Kaiser · Alan F. Cruess · Peter Bogaert · Kamlesh Khunti · Simon P. Kelly

Published online: 10 January 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-012-2123-4

Unfortunately, two references were mistakenly omitted in the bibliography of the original version of this manuscript and five citation errors occurred, which are listed below with the correct citation information only.

- Page 1565, second sentence of the first paragraph:
  “Importantly, the initial clinical trials of rosiglitazone were not designed to generate cardiovascular safety outcomes data, and this AE was not detected [26].”

26. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471

- Page 1565, third sentence of the third paragraph:
  “The concept of informed consent for off-label/unlicensed use is reflected in the European Convention of Human Rights and associated case law, as well as in national laws and ethical guidance [36].”

36. Molyneux CG, Bogaert P (2010) The need for informed consent in off-label use in the EU. Regulatory Affairs Pharma November:13–16

- Page 1567, first sentence of the first paragraph:
  “It is important to note that in Year 1 there were no differences in venous thrombolic events or ATEs; however, there was a significantly higher rate of serious systemic AEs (of which 80.5% were associated with hospitalisation) with bevacizumab compared with ranibizumab, which remained significantly higher after adjustment for baseline demographics and coexisting illnesses (p=0.04) [16].”

16. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908

- Page 1568, third sentence of the third paragraph:
  “Only in recent years, following public and media interest in high-profile drug safety cases such as those of rosiglitazone and rofecoxib (Vioxx®, Merck, Whitehouse Station, NJ, USA), is the process of proving drug safety receiving similar attention to the process of demonstrating efficacy, and this has led to reform of EU pharmacovigilance laws [77].”

The online version of the original article can be found at http://dx.doi.org/10.1007/s00417-012-2123-4.

P. K. Kaiser (✉)
Cole Eye Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk i32, Cleveland, OH 44195, USA
e-mail: pkkaiser@aol.com

A. F. Cruess
Department of Ophthalmology and Visual Sciences, Dalhousie University, Nova Scotia, Canada

P. Bogaert
Covington & Burling LLP, Brussels, Belgium

K. Khunti
Department of Health Sciences, University of Leicester, Leicester, UK

S. P. Kelly
Royal Bolton Hospital NHS Foundation Trust, Bolton, UK
Page 1568, the last sentence of the third paragraph:

“For example, the Royal College of Ophthalmologists has provided detailed guidance on patient safety in ophthalmology, which should be of merit to eye-care teams to improve patient safety in local departments and aims to keep members updated of emerging issues [78,79].”

78. Kelly SP (2011) Update on patient safety. Br J Ophthalmol 95:1183-1184

79. The Royal College of Ophthalmologists. Patient safety in ophthalmology. The Royal College of Ophthalmologists, London. February 2011. Available at http://www.rcophth.ac.uk/core/core_picker/download.asp?id=852&filetitle=Patient+Safety+in+Ophthalmology+February+2011.

Page 1568, the fourth sentence of the fourth paragraph:

“Existing clinical evidence comes solely from clinical studies, with a number of studies reporting trends towards an increased risk of systemic AEs with bevacizumab [16–18, 59–61].”

16. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908
17. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398
18. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
59. Carneiro AM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, Gonçalves R, Fonseca SL, Gafà Correia F, Falcão-Reis FM, Soares R (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25–e30
60. Carneiro AM, Barthelmes D, Falcão MS, Mendonça LS, Fonseca SL, Gonçalves RM, Faria-Correia F, Falcão-Reis FM (2011) Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 225:211–221
61. Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128:1273–1279